Clinical trials in Przasnysz

3 clinical trials in Przasnysz, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Przasnysz at a glance

clinical trials

Paediatric trials0
Research sites0

Quick filters

3 trials in Przasnysz

Open in trial search

Myocardial infarction

Recruiting

Study on the Effects of Ferric Carboxymaltose on Heart Health and Quality of Life in Patients with Recent Heart Attack and Iron Deficiency

Registered drug

Study on the Effects of Ferric Carboxymaltose on Heart Health and Quality of Life in Patients with Recent Heart Attack and Iron Deficiency

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Agencja Badań Medycznych

Contact Research Centre

Cardiac failure

Not yet recruiting

Study on COR-1167 for Patients with Worsening Heart Failure

Investigational

Study on COR-1167 for Patients with Worsening Heart Failure

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:Corteria Pharmaceuticals

Contact Research Centre

Cardiac failure acute

Not recruiting

Study of dapagliflozin effects in patients hospitalized with acute heart failure

Registered drug

Study of dapagliflozin effects in patients hospitalized with acute heart failure

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Dapagliflozin Propanediol Monohydrate
Sponsor:The Brigham And Women’s Hospital Inc.

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Przasnysz

What the registry says about research in the country

01 Cardiovascular Research

Clinical investigations focusing on myocardial infarction patients with concurrent iron deficiency. The research evaluates innovative intravenous treatments to improve cardiovascular outcomes and patient wellbeing.

Heart Failure Management
Quality of Life Assessment
Cardiovascular Mortality

Studies aim to understand the impact of ferric carboxymaltose treatment on mortality rates and heart failure-related events, while monitoring patients' quality of life improvements over a three-year period.

Back to Poland All countries